Alluvi, formerly BI 4744, presents a notable advance in obesity care. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates remarkable efficacy in research studies, possibly surpassing https://atozbookmarkc.com/story22358652/alluvi-a-detailed-dive-into-the-medication-s-prospects